Mesoblast stock: November 10 AGM backs board and pay resolutions

Published on 11/13/2026 at 20:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mesoblast stock faces a governance reset after the November 10 annual meeting. Shareholders approved all listed resolutions, including Jon Voigtman's election.

Governance and pipeline milestones

Shareholders approved all resolutions at Mesoblast's November 10 annual meeting, including the election of Jon Voigtman.
The company is preparing for a chronic low back pain trial readout in the second half of calendar 2027.
Mesoblast reported first-year Ryoncil net revenue of US$115 million for fiscal 2026.

Mesoblast stock, annual general meeting, Jon Voigtman, Ryoncil, rexlemestrocel-L, Illustration mit AI erstellt.

Mesoblast shareholders approved all listed resolutions at the company's annual general meeting on Tuesday, November 10, including the election of Jon Voigtman as a director. The results were included in a Mesoblast Form 6-K filing.

Voigtman received 81.22% of votes cast in the poll, while the remuneration report passed with 72.06%. Shareholders also approved the restricted stock unit plan and proposed equity awards and warrants for directors and executives.

Board approval supports commercial transition

The meeting outcome comes as Mesoblast shifts from clinical development toward commercial execution. The company said fiscal 2026 net product revenue from Ryoncil reached US$115 million, while gross profit on total sales excluding amortization expense was US$110 million.

Mesoblast also reported that 350 patients had been enrolled in the Phase 3 trial of rexlemestrocel-L for chronic low back pain. The company targets a trial readout in the second half of calendar 2027, followed by a planned Biologics License Application filing if the results support that step.

Pipeline work sets the next milestones

The company said it had aligned with the U.S. Food and Drug Administration on a filing for rexlemestrocel-L in end-stage heart failure patients with left ventricular assist devices. Mesoblast is also searching for a permanent chief operating officer while Dr. Gregory George serves in the interim role.

Mesoblast stock traded at 1.21 euros on Lang & Schwarz at 20:38 CET on Friday, November 13.